One of the most important psychedelic drug discovery companies in the world is starting to prepare for how psychedelic assisted therapies will actually reach patients in a clinical setting.
What’s happening:
- Psychedelic biotechnology company COMPASS Pathways (NASDAQ: CMPS) has entered into a new multi year research collaboration with Greenbrook TMS (NASDAQ: GNBH)
- The focus of the partnership between COMPASS and Greenbrook will be exploring potential ways to integrate psychedelic assisted therapies in a clinical setting and ensure the best patient outcomes possible
Why it matters:
- COMPASS Pathway’s lead drug candidate COMP360 is a synthetic psilocybin compound meant to be administered with the guidance of a therapist
- Greenbrook has an extensive clinical network across the United States, with many of their existing patients being a potential future fit for COMP360
- Beginning to build data based frameworks for how psychedelic assisted therapies will actually be administered is a critical step forward for psychedelic therapeutics integrating into existing healthcare infrastructure
Going deeper:
- COMP360 is currently in a Phase III trial for Treatment Resistant Depression after overwhelmingly positive results from their Phase I and Phase II trials
- The FDA has already designated COMP360 as a “Breakthrough Therapy” for Treatment Resistant Depression
- Upon completion of the Phase III clinical trial, COMPASS Pathways intends to seek FDA approval for being able to administer COMP360 in clinics across the United States
By the numbers:
- In the successful Phase II clinical trial for COMP360, patients who received a single 25mg dose of COMP360 saw significant improvements in their symptoms within just 3 weeks
